AIMS: Endometrial cancer is one of the most common cancers in women worldwide, but there is a lack of diagnostic markers for early detection of these tumours. The raf kinase inhibitory protein (RKIP) negatively regulates the Raf/MEK/ERK pathway, and the downregulation of RKIP is associated with tumour progression and metastasis in several human neoplasms. The aim of this study was to assess the expression levels of RKIP in endometrial cancer and determine whether this expression correlates with clinical outcome in these patients. METHODS: Tissue microarrays constructed using tissue samples from 209 endometrial adenocarcinomas, 49 endometrial polyps and 48 endometrial hyperplasias were analysed for RKIP expression by immunohistochemistry. RESULTS: The authors found that RKIP expression decreases significantly during malignant progression of endometrial cancer; it is highly expressed in non-neoplastic tissues (polyps 79.6%; hyperplasias 87.5%) and expressed at very low levels in endometrioid adenocarcinomas (29.7%). No correlations were observed between RKIP expression, clinicopathological data and survival. CONCLUSION: This study demonstrated for the first time that RKIP expression is lost during the carcinogenic evolution of endometrial tumours and that the loss of RKIP expression is associated with a malignant phenotype. Functional studies are needed to address the biological role of RKIP downregulation in endometrial cancer.
AIMS: Endometrial cancer is one of the most common cancers in women worldwide, but there is a lack of diagnostic markers for early detection of these tumours. The raf kinase inhibitory protein (RKIP) negatively regulates the Raf/MEK/ERK pathway, and the downregulation of RKIP is associated with tumour progression and metastasis in several humanneoplasms. The aim of this study was to assess the expression levels of RKIP in endometrial cancer and determine whether this expression correlates with clinical outcome in these patients. METHODS: Tissue microarrays constructed using tissue samples from 209 endometrial adenocarcinomas, 49 endometrial polyps and 48 endometrial hyperplasias were analysed for RKIP expression by immunohistochemistry. RESULTS: The authors found that RKIP expression decreases significantly during malignant progression of endometrial cancer; it is highly expressed in non-neoplastic tissues (polyps 79.6%; hyperplasias 87.5%) and expressed at very low levels in endometrioid adenocarcinomas (29.7%). No correlations were observed between RKIP expression, clinicopathological data and survival. CONCLUSION: This study demonstrated for the first time that RKIP expression is lost during the carcinogenic evolution of endometrial tumours and that the loss of RKIP expression is associated with a malignant phenotype. Functional studies are needed to address the biological role of RKIP downregulation in endometrial cancer.
Authors: Márcia Santos Pereira; Sónia Pires Celeiro; Ângela Margarida Costa; Filipe Pinto; Sergey Popov; Gisele Caravina de Almeida; Júlia Amorim; Manuel Melo Pires; Célia Pinheiro; José Manuel Lopes; Mrinalini Honavar; Paulo Costa; José Pimentel; Chris Jones; Rui Manuel Reis; Marta Viana-Pereira Journal: Cell Oncol (Dordr) Date: 2019-11-07 Impact factor: 6.730
Authors: Márcia Santos Pereira; Gisele Caravina de Almeida; Filipe Pinto; Marta Viana-Pereira; Rui Manuel Reis Journal: J Histochem Cytochem Date: 2015-10-06 Impact factor: 2.479
Authors: Olga Martinho; Sara Granja; Teresa Jaraquemada; Cláudia Caeiro; Vera Miranda-Gonçalves; Mrinalini Honavar; Paulo Costa; Margarida Damasceno; Marsha R Rosner; José M Lopes; Rui M Reis Journal: PLoS One Date: 2012-01-23 Impact factor: 3.240
Authors: Olga Martinho; Filipe Pinto; Sara Granja; Vera Miranda-Gonçalves; Marise A R Moreira; Luis F J Ribeiro; Celso di Loreto; Marsha R Rosner; Adhemar Longatto-Filho; Rui Manuel Reis Journal: PLoS One Date: 2013-03-19 Impact factor: 3.240